3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
17
Recurrence
9
Lymphoma, Large B-Cell, Diffuse
7
Endometrial Neoplasms
4
Lymphoma, T-Cell, Peripheral
3
Glioblastoma
3
Colorectal Neoplasms
3
Sarcoma
2
Primary Myelofibrosis
2
Neoplasms
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Carcinoma, Squamous Cell
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Richter's Transformation
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Temozolomide
17
Radiotherapy
8
Surgical Procedures, Operative
6
Flucytosine
6
vocimagene amiretrorepvec
5
IL13-PE38
5
Lomustine
4
Valacyclovir
3
Radiation
3
Corticotropin-Releasing Hormone
3
Chlorotoxin
3
Carmustine
3
Bevacizumab
3
vorasidenib
2
trametinib
2
tovorafenib
2
regorafenib
2
pembrolizumab
2
paclitaxel-Angiopep-2 conjugate
2
dabrafenib
2
Trabedersen
2
OKN 007
2
Nivolumab
2
Everolimus
2
Eflornithine
2
Drug Delivery Systems
2
Carboplatin
2
Cancer Vaccines
2
Adjuvants, Immunologic
2
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Astrocytoma
×
selinexor
×
Clear all
NCT01986348
2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2
Terminated
76 enrolled
16 charts